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Epstein–Barr virus (EBV) encodes for several enzymes that are involved in viral DNA replication. There is evidence that some viral proteins,
by themselves, can induce immune dysregulation that may contribute to the pathophysiology of the virus infection. In this study, we focused on
the EBV-encoded deoxyuridine triphosphate nucleotidohydrolase (dUTPase) and present the first evidence that the dUTPase is able to induce
immune dysregulation in vitro as demonstrated by the inhibition of the replication of stimulated peripheral blood mononuclear cells (PBMCs) and
the upregulation of several proinflammatory cytokines including TNF-a, IL-1h, IL-8, IL-6, and IL-10 produced by unstimulated PBMCs treated
with purified EBV-encoded dUTPase. Depletion of CD14-positive cells (monocytes) eliminated the cytokine profile induced by EBV dUTPase
treatment. The data support the hypothesis that at least one protein of the EBV early antigen complex can induce immune dysregulation and may
be involved in the pathophysiology of EBV-associated disease.
D 2005 Elsevier Inc. All rights reserved.Keywords: Monocytes/macrophages; Epstein–Barr virus; Cytokines; Tumor immunity; CancerIntroduction
Epstein–Barr virus (EBV), a gamma herpesvirus, is the
causative agent of infectious mononucleosis (IM) and is
implicated in the pathogenesis of a variety of human malignan-
cies including Burkitt’s lymphoma (BL), nasopharyngeal carci-
noma (NPC), Hodgkin’s disease, T-cell lymphoma, and post-
transplant lymphoproliferative disorder (Ablashi et al., 1990;
Brousset, 2002; Petrella et al., 1997; Touitou et al., 2003). In
recent years, EBV-associated malignancies have become in-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.10.034
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E-mail address: glaser.1@osu.edu (R. Glaser).creasingly common especially in transplant patients and patients
with acquired immunodeficiency syndrome (Ho et al., 1988).
Following infection and replication of EBV in B-lympho-
cytes, there are changes in the secretion patterns of TNF-a,
interleukin-1 (IL-1), interleukin-6 (IL-6), and interleukin-10 (IL-
10) (Fayad et al., 2001; Gosselin et al., 1991, 1992a, 1992b;
Tanner et al., 1996). These changes in cytokine expression and
immune dysregulation are due in part to the interaction of gp350/
220 (gp350), the major envelope glycoprotein encoded by EBV,
and CR2, the cellular receptor for EBV on B-lymphocytes.
Increases in serum levels of IL-10, IL-6, TNF-a, IL-1h, and IL-
8 levels in patients with EBV-associated lymphomas have been
described (Klein et al., 1996; Kurzrock, 2001; Luciani et al.,
1998; Mori et al., 2003; Sharma and Zhang, 2001), and serum
levels of both IL-6 and IL-10 have been correlated with disease6) 205 – 218
www.e
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predictive of a poorer health outcome (Fayad et al., 2001; Lai
et al., 2002). There is evidence that IL-10 can act as a growth
factor for EBV-related tumors (Miyazaki et al., 1993). In a recent
study, increased levels of IL-10 were also observed in serum
from NPC patients and in the tumor cells (Budiani et al., 2002).
Cellular IL-10 is produced by Type 2 helper cells (Th-2),
monocytes/macrophages, and B-cells and can inhibit the
production of cytokines from Type 1 helper cells (Th-1),
including interferon-gamma (IFN-g) and IL-2 (Fiorentino et al.,
1989). Because Th-1 cytokines are important for controlling virus
infection, including the production of virus-specific cytotoxic T-
lymphocytes targeting EBV-infected cells, this shift in the Th-1
pattern to a Th-2 pattern favors virus-induced pathogenesis.
There are recent studies which suggest that some EBV-
encoded proteins can induce immune dysregulation when
purified and tested in vitro. Data from one study showed that
purified EBV latent membrane protein-1 (LMP-1), which is
expressed in latently infected cells, was able to suppress T-cell
and natural killer (NK) cell responses (Dukers et al., 2000).
Another study using the purified gp350 showed that this late
structural viral protein was able to upregulate TNF-a gene
expression in human monocytes (D’Addario et al., 2000).
Because EBV encodes for approximately 70 polypeptides,
undoubtedly, more than these two (i.e., LMP-1 and gp350) will
have the potential to modulate immune function.
EBV, like other herpesviruses, encodes for several enzymes
that are involved in viral DNA replication; all are part of the
early antigen (EA) complex. Thus far, six EBV-associated
enzymes have been described. Our laboratory helped describe
several of these enzymes, including the thymidine kinase (TK),
DNA polymerase, deoxyribonuclease (DNase), dUTPase, and
ribonucleotide reductase (Cheng et al., 1980; Glaser et al.,
1973; Goodman et al., 1978; Henry et al., 1978; Miller et al.,
1977; Williams et al., 1985). The EBV also encodes for a
uracil–DNA glycosylase (Baer et al., 1984). Studies to
determine whether any of these enzymes modulate immune
function have not been performed.
In this report, we present the first evidence that the EBV-
encoded dUTPase is able to induce immune dysregulation in
vitro as demonstrated by its effect on the replication of PBMCsTable 1
Interpretable mass spectra and the corresponding sequence from the solution diges
Protein Observed m/z Experimental MW Predicted MW
dUTPase 765.49+2 1528.96 1528.82
976.10+2 1950.18 1950.03
1021.10+2 2040.18 2040.02
923.82+3 2768.45 2768.24
1385.26+2 2768.50 2768.24
Trypsin 421.80+2 841.58 841.50
737.76+3 2210.26 2210.10
1106.15 2210.30 2210.10
A total of 8 MS/MS spectra were observed with quality fragment ions, 5 account for
from trypsin. The peptide corresponding to amino acids 243–268 is observed as bot
encoded dUTPase.and the production of several different proinflammatory
cytokines including IL-1h, TNF-a, IL-6, IL-8, and IL-10. We
hypothesize that the immune dysregulation induced by EBV-
encoded dUTPase, and perhaps other viral proteins, plays a role
in the pathophysiology of EBV-associated disease. We
provided data to support this hypothesis in a previous report,
which showed that EBV-encoded dUTPase modulated immune
function in mice and that these immune changes were
associated with the induction of sickness behavior (Padgett et
al., 2004).
Results
Purification of the EBV-encoded dUTPase
The recombinant EBV-encoded dUTPase preparations were
routinely purified 450 to 750-fold using Blue Sepharose
affinity chromatography followed by concentration. The
identification and purity of the EBV-encoded dUTPase were
assessed using mass spectrometry and proteomic-based tech-
niques. The sample was digested using trypsin, and the
peptides were analyzed using nano-LC/MS/MS. Using Mascot,
the EBV-encoded dUTPase was identified with a 27%
sequence coverage and a significant score of 193 where
individual ion scores of >53 indicate identity or extensive
homology. Trypsin was matched with a score of 88. However,
trypsin was used as the proteolytic enzyme, and two autolysis
peaks are commonly observed in all samples digested with
trypsin. No other proteins were identified with any signifi-
cance, and all interpretable MS/MS spectra were accounted for
as either the EBV-encoded dUTPase or trypsin.
The total number of interpretable MS/MS spectra was eight,
and the results are shown in Table 1. The peptide from amino
acid 243–268 was observed as both a doubly and triply
charged ion, therefore, five interpretable MS/MS spectra match
sequences from the EBV-encoded dUTPase with four unique
peptides matching the EBV-encoded dUTPase. A typical MS/
MS spectrum of the peptides observed and sequenced on the Q-
TOFi is shown in Fig. 1. The MS/MS spectrum depicts the
tryptic peptide from the solution digestion of the EBV-encoded
dUTPase with m/z 765.5 + 2. The sequence corresponds totion with trypsin of purified EBV-encoded dUTPase
D MW Sequence
0.14 172SGLAMQGILVKPCCAMR
185
0.15 9YAFQNDKLLLQQASVGR25
0.17 189GGVDVSLTNFSDQTVFLNK207
0.20 243WATCCAMAFEEVPGLAMOXGDSGLSEALEGR
268
0.26 243WATCCAMAFEEVPGLAMOXGDSGLSEALEGR
268
0.08 108VATVSLPR115
0.16 58LGEHNIDVLEGNEQFINAAK77
0.20 58LGEHNIDVLEGNEQFINAAK77
sequences from the EBV-encoded dUTPase and 3 account for autolysis peptides
h a doubly and triply charged ions making four unique peptides from the EBV-
Fig. 1. MS/MS spectrum of a tryptic peptide from the solution digestion of the EBV-encoded dUTPase with m/z 765.5 + 2. The assigned b/y ions are labeled and
listed in Table 2. The sequence corresponds to 172SGLAMQGILVKPCCAMR
185.
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185. The assigned b/y ions are
labeled and listed in Table 2.
EBV-encoded dUTPase has an inhibitory effect on the
blastogenic response of human PBMCs stimulated with an
anti-CD3 mAb
The treatment of PBMCs with the EBV-encoded dUTPase
significantly inhibited anti-CD3-mAb-induced blastogenesis
of cells obtained from eight individuals (two-tail P < 0.015
for 7.5 Ag/ml and P < 0.01 for 15 Ag/ml EBV-encoded
dUTPase) (Fig. 2). Using PBMCs from three of these
subjects, we found that inhibition of the blastogenic response
of T-cells by EBV-encoded dUTPase was dose-dependent
with saturation occurring around 1 Ag/ml. Human g-globulin
was used as a non-specific protein control and did not
significantly affect anti-CD3-mAb-induced blastogenesis at
similar concentrations (Fig. 3).
EBV-encoded dUTPase can induce cytokine production by
resting unstimulated human PBMCs
We examined EBV-encoded dUTPase-treated PBMCs for
cytokine production in cell supernatants. Incubation of non-
stimulated resting PBMCs with EBV-encoded dUTPase causedTable 2
Representative coverage of b and y ion series from a tryptic peptides from dUTPas
Shaded boxes indicate peaks assigned have a minimum S/N ratio of 3 and are within
this example of the b/y ion series, 77% of the b ions are observed and 85% of y ioa rapid production/release of TNF-a that peaked at 24 h and
quickly declined over time (Fig. 4A). Figs. 4B and C
respectively show that EBV-encoded dUTPase can induce IL-
10 and IL-1h production by human PBMCs, which reached a
maximum at 24 h and slowly declined over time. IL-6 and IL-
8 production was also greatly enhanced and sustained over time
when the PBMCs were cultured with EBV-encoded dUTPase
(Figs. 4D and E). No IL-2, IL-4, IL-5, or IL-12 p70 was detected
in cell supernatants treated with the EBV-encoded dUTPase.
Although EBV dUTPase treatment of resting PBMCs
induced inflammatory cytokines, IFN-g levels in dUTPase-
treated cells were not significantly different from the control
cultures and were found to be within the range of 0–500 pg/ml.
However, upon treatment of the cells with 0.8 Ag/ml of the CD3
mAb used in the T-cell blastogenesis assay, IFN-g levels
increased 5- to 10-fold in control PBMCs cultures obtained
from six out of eight individuals. Concurrent treatment of the
PBMCs with EBV dUTPase and the CD3mAb resulted in lower
IFN-g levels when compared to the control cultures from the
same individuals. Two out of the eight individuals did not release
any IFN-g regardless of treatment. While the results were not
statistically different, there was a trend showing that IFN-g
production was suppressed after 48 h when the PBMCs were
incubated with EBV-encoded dUTPase (Fig. 4F, P < 0.084 for
7.5 Ag/ml and P < 0.064 for 15 Ag/ml EBV dUTPase, n = 8).e corresponding to amino acid sequence 172–185
0.2 Da of predicted. Bold black indicates a peak assignment with a S/N at 3. In
ns are observed.
Fig. 2. The effect of EBV-encoded dUTPase on the replication of PBMCs
stimulated with an anti-CD3 mAb. PBMCs were incubated for 72 h with various
concentrations of an anti-CD3 mAb to induce T-cell blastogenesis. The data are
presented as the change in optical density from non-stimulated and CD3-
stimulated cells. The PBMCs were treated with EBV-encoded dUTPase (cross-
hatched bars) at the same time the mAb was added. Results are the mean T SEM;
n = 8. Untreated PBMCs ( ), 7.5 Ag/ml EBV dUTPase ( ), and 15 Ag/ml
EBV dUTPase ( ).
Fig. 3. Dose-dependent inhibition of the replication of PBMCs stimulated with
an anti-CD3 mAb by EBV-encoded dUTPase. PBMCs were incubated with 0.8
Ag/ml of an anti-CD3 mAb for 72 h as described in Materials and methods. The
cells were treated with various concentrations of EBV-encoded dUTPase. The
results are shown as the mean T SEM; n = 3. Untreated PBMCs ( ), EBV
dUTPase ( ), and human g-globulin ( ).
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dUTPase enhanced levels of TNF-a, IL-1h, IL-10, IL-,6 and IL-
8 approximately two-fold when compared to dUTPase-treated
PBMCs (data not shown).
Studies on the purity of the EBV dUTPase preparations
It was important to be sure that the purified EBV dUTPase
preparations were not contaminated with factors, such as LPS,
DNA, RNA, and peptidoglycan, that could produce the
cytokine patterns observed. We had already shown that the
EBV dUTPase preparations contained no other protein as
determined by nano-LC/MS/MS.
Standard assays (Limulus Lysate, Quant-iTi and SLP-HS)
used for the detection and quantitation of LPS, dsDNA, RNA,
and peptidoglycan demonstrated that the amount of LPS,
dsDNA, RNA, or peptidoglycan was below the detection limits
of these assays, which suggests that the EBV-encoded
dUTPase preparations were free of these contaminates (data
not shown).
In order to ensure that immunoregulatory effects were
produced by the EBV-encoded dUTPase, a series of experi-
ments were performed to demonstrate that the effects were
not the result of contaminating LPS. Briefly, PBMCs were
treated in a dose–response manner with LPS (0.001 to 10 Ag/
ml), and the supernatants examined for the production of
cytokines. PBMCs were also treated with EBV-encoded
dUTPase (10 Ag/ml) in the presence and absence of
polymyxin B (10 Ag/ml); the supernatants were examined
for the production of cytokines. Finally, PBMCs were treated
with EBV-encoded dUTPase in the presence and absence of
the 7D6 mAb, the supernatants were examined for the
production of cytokines. The results for TNF-a as a
representative example are shown in Fig. 5.Treatment of the PBMCs with LPS resulted in a dose–
response increase in TNF-a production (Fig. 5A). Extrapola-
tion of the data when PBMCs from the same preparation were
treated with 10 Ag/ml EBV dUTPase in which 1425 pg/ml
TNF-a was induced at 24 h suggests that it would take 6.2 Ag/
ml LPS to induce equivalent levels of TNF-a when compared
to the EBV-encoded dUTPase. Based upon 1 ng LPS being
equivalent to 1–10 IU, the 6.2 Ag/ml LPS would be equivalent
to a minimum of 620 IU of LPS/ml and would be easily
detectable by the Limulus lysate assay which has a sensitivity
of 0.06 IU of LPS/ml. Secondly, as shown in Fig. 5B,
polymyxin B, an inhibitor of LPS, had no significant effect on
TNF-a induction by the EBV-encoded dUTPase. Finally, the
7D6 mAb significantly inhibited the induction of TNF-a by
the EBV-encoded dUTPase (P < 0.025, Fig. 5C). Similar
results were obtained with the other cytokines (data not
shown).
EBV-encoded dUTPase-induced cytokine profile predominately
involves monocytes/macrophages
While performing the blastogenesis studies, we obtained
preliminary data suggesting that the percentage of CD14+ cells
in each PBMC preparation (as determined by flow cytometry)
was related to the ability of the EBV-encoded dUTPase to
inhibit T-cell division. Furthermore, the cytokine profile
induced by EBV-encoded dUTPase treatment also suggested
involvement of monocytes/macrophages. In order to test this
hypothesis, we performed a series of depletion studies using
MACS (see Figs. 6A–C). Removal of CD14+ cells totally
eliminated the cytokine pattern observed with PBMCs treated
with EBV-encoded dUTPase (Figs. 7A–E). Additionally,
treatment of the adherent fraction, which was enriched for
monocytes (68% CD14+ cells, Fig. 6C), with EBV-encoded
dUTPase showed a cytokine profile similar to the response of
Fig. 4. (A–F) The effect of EBV-encoded dUTPase on cytokine production. PBMCs were treated with two different concentrations of EBV-encoded dUTPase as
described in Materials and methods. Untreated PBMCs (.), 7.5 Ag/ml EBV-encoded dUTPase (˝), and 15 Ag/ml EBV-encoded dUTPase (r). Cell supernatants
were assayed for cytokine levels at 24, 48, and 72 h. The results are the mean T SEM; n = 8. The inserted bar-graph plots represent the relative change in cytokine
mRNA expression at 24 h. Untreated PBMCs ( ), 7.5 Ag/ml EBV dUTPase ( ), and 15 Ag/ml EBV dUTPase ( ).
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the total cell number was used (Figs. 7A–E). We chose to test
the adherent fraction to avoid any effects of the CD14 antibody
on the cells. In experiments in which the adherent cells (CD14-
enriched) were added back, the cytokine pattern was re-
established in a concentration-dependent manner (see insertedbar-graphs within Figs. 7A–E). The enrichment of CD14+
cells by adherence was variable with each preparation. The
results shown in Fig. 7 represent data obtained from the sample
in which we obtained the highest purity of macrophages/
monocytes. Figs. 8A–E show the correlations between the
actual number of CD14+ cells added back and EBV-encoded
Fig. 5. (A–C) The determination of the purity of the EBV dUTPase
preparations using TNF-a as the outcome measure. PBMCs were treated with
10 Ag/ml EBV-encoded dUTPase as described in Materials and methods.
Experiments were performed at least three times, and a typical profile is shown
in this figure. The results shown are the average T SD for duplicate assays. (A)
Dose-dependent induction of TNF-a by LPS. Arrows indicate the amount of
LPS needed to induce the equivalent amount of TNF-a by 10 Ag/ml EBV
dUTPase at 24 h. (B) Control, polymyxin B sulfate (.), EBV-encoded
dUTPase (˝), and EBV-encoded dUTPase plus polymyxin B sulfate (r). (C)
Control, mAb 7D6, or Rat IgG1 Isotype (.), EBV-encoded dUTPase plus rat
IgG1 isotype (˝), and EBV-encoded dUTPase plus mAb 7D6 (r). Cell
supernatants were assayed for cytokine levels at 24, 48, and 72 h.
Fig. 6. (A–C) Flow cytometry analyses of CD14 depletion by MACS. CD14
depletion was performed as described in Materials and methods. Flow cytometry
analysis was done using a BD FACSCalibur Flow Cytometer. Depletion and
adherent experiments were performed at least three times, and a typical analysis is
shown in this figure.Monocytes/macrophages are larger and havemore granularity
than the lymphocytes and are located in the upper right of the ellipse in the side
scatter vs. forward-scatter plot before depletion (left panel A). The monocyte
macrophage population is absent after CD14 depletion (left panel B) and enriched
in the adherent fraction (left panel C). This individual’s PBMCs had 18% CD14+
cells before depletion (right panel A) and none after depletion (right panel B). The
adherent fraction was enriched with 68% CD14+ cells (right panel C).
R. Glaser et al. / Virology 346 (2006) 205–218210dUTPase-induced cytokine production. These preliminary data
suggest that monocytes/macrophages are the primary cell type
being affected by the EBV-encoded dUTPase.Discussion
While studies have demonstrated that the major capsid
protein gp350 and LMP-1 of EBV modulates the immune
response (D’Addario et al., 2000; Dukers et al., 2000), little is
known concerning whether other EBV-encoded proteins are
immunomodulatory. In this study, we demonstrate that the EBV-
encoded dUTPase induces immune dysregulation. The purified
protein inhibited anti-CD3-mAb-induced blastogenesis. Fur-
thermore, the EBV-encoded dUTPase stimulated the production
of cytokines in non-stimulated resting human PBMCs. The
production of IL-1h, IL-6, IL-8, and IL-10 proteins was-
/
Fig. 7. (A–E) EBV-encoded dUTPase-induced cytokine profile predominately involves monocytes/macrophages. Cell fractions were treated with 10 Ag/ml EBV-
encoded dUTPase as described in Materials and methods. Depletion and adherent experiments were performed at least three times, and a typical profile is shown in
this figure. The results shown are the average T SD for duplicate assays. Control, PBMCs before depletion (.), adherent fraction (˝), and CD14-depleted fraction
(r). Cell supernatants were assayed for cytokine levels at 24, 48, and 72 h. The inserted bar-graph plots show the change in cytokine expression at 24 h when the
adherent fraction was added back to the CD14-depleted fraction (cross-hatched bars).
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TNF-a mRNA levels were detected at 3 and 6 h after dUTPase
treatment. Interestingly, TNF-a was also detected by flow
cytometry 3 and 6 h post-treatment at approximately 500 pg/mland 1000 pg/ml, respectively (data not shown). The elevated
TNF-a levels detected by ELISA could have resulted from de
novo synthesis or release of the membrane-anchored TNF-a
precursor. Although it was not our intention to perform an
Fig. 8. (A–E) Correlation of CD14+ cells with EBV-encoded dUTPase-induced cytokine production. Cytokine production (average T SD) was plotted against the
actual number of CD14+ cells added back to the CD14-depleted fraction as determined from flow analysis of the adherent fraction. The coefficients of correlation are
reported within the figures. The results were obtained from three different adherent/depleted fractions.
R. Glaser et al. / Virology 346 (2006) 205–218212extensive kinetic study on the induction of cytokine expression
by dUTPase, data collected at 24, 48 and 72 h allowed us to draw
conclusions concerning the changes in expression over the
course of treatment as compared to control cultures.
Furthermore, we demonstrate conclusively that the EBV-
encoded dUTPase is responsible for inducing the immunedysfunction. Nano-LC/MS/MS was used to demonstrate that
the EBV-encoded dUTPase was purified to homogeneity. To
eliminate the possibility that the results of these studies with
the purified EBV-encoded dUTPase were due to LPS, DNA,
RNA, or peptidoglycan contamination, additional studies were
performed. The Limulus lysate reaction, which has a detection
R. Glaser et al. / Virology 346 (2006) 205–218 213limit of 0.06 IU of LPS per ml, was negative. Assuming that
the EBV-encoded dUTPase preparations were contaminated
with LPS at a level of 0.05 IU per ml and that 1 IU is
equivalent to 1 ng of LPS, then the maximum level of LPS that
could be present in any assay was 0.03 ng or 0.03 IU. Control
studies demonstrated that at least 6 Ag/ml of LPS was required
to induce equivalent production of TNF-a when compared to
the EBV-encoded dUTPase (10 Ag/ml). Furthermore, the
addition of polymyxin B (10 Ag/ml) did not have any effect
on the ability of the EBV-encoded dUTPase to induce cytokine
expression. Likewise, we demonstrated using the high sensi-
tivity Quant-iTi dsDNA and RNA assay systems, which have
a detection limit of 1 ng/ml of dsDNA and 5 ng/ml for RNA,
that the EBV-encoded dUTPase preparations were negative.
Assuming that the EBV-encoded dUTPase preparations
contained 0.9 ng of DNA/ml, then the maximal amount of
dsDNA that could be present in any assay is 0.5 ng which is at
least 3-fold less that what has been reported previously to
stimulate Toll receptors (TLR) (Ahmad-Nejad et al., 2004). We
also demonstrated using the SLP-HS assay, which has a
detection limit of 10 pg/ml of peptidoglycan, that the EBV-
encoded dUTPase preparations were free of contaminating
peptidoglycan. Finally, the 7D6 mAb, which was prepared
against the EBV dUTPase, prevented the induction of the
cytokines by the EBV-encoded dUTPase. The results provide
conclusive data demonstrating that the EBV-encoded dUTPase
preparations are free of contaminating proteins, LPS, DNA,
RNA, and peptidoglycan, thus further supporting our premise
that the EBV-encoded dUTPase induces immune dysfunction.
The mechanism(s) through which EBV-encoded dUTPase
may influence the immune response is suggested by the
depletion/add-back experiments showing the role of CD14+
cells with the effect of dUTPase on PBMCs. Macrophages, as
well as dendritic cells, polymorphonuclear cells, and NK cells,
discriminate between foreign pathogens and self through
signals mediated by pattern recognition receptors (PRR), which
include the TLRs, scavenger receptors, complement receptor,
members of the C-type lectin receptor family, and integrins
(Fiorentino et al., 1991). TLRs recognize conserved motifs
present in pathogens and when stimulated trigger a signaling
cascade that leads to the activation of NF-nB and the enhanced
transcription of inflammatory cytokines genes (O’Neill, 2002).
Our premise is that the EBV-encoded dUTPase is a pathogen-
associated molecular pattern (PAMP) that triggers a signaling
cascade following its interaction with an TLR.
While the EBV-encoded dUTPase is only expressed during
virus replication, there is accumulating evidence suggesting
that abortive-lytic replication occurs in vitro and in vivo and
that the immediate-early and early viral gene products affect
cellular functions (Glaser et al., 1991, 2005). It was recently
reported that EBV lytic and abortive-lytic replication occurs in
plasma cells located in the tonsils of healthy individuals
(Laichalk and Thorley-Lawson, 2005). Furthermore, several
human herpesviruses, including EBV, are reported to infect
monocytes and to undergo lytic replication in vitro (Blasig et
al., 1997; Gosselin et al., 1991; Ibanez et al., 1991; Savard et
al., 2000). It has been reported previously that the EBV-encoded dUTPase could be detected in epithelial cell layers of
the tongue in patients with oral hairy leukoplakia and in
lymphoid cells in the tonsils of patients with IM (Fleischmann
et al., 2002). Likewise, antibodies to the EBV-encoded
dUTPase have been detected in some patients with IM, chronic
EBV infection, and HIV infection, but not in normal EBV-
seropositive individuals or EBV negative subjects (Sommer et
al., 1996). We now have preliminary data that show that NPC
patients also have antibody to EBV-encoded dUTPase (data not
shown). These results suggest that significant amounts of EBV-
encoded dUTPase are expressed during lytic and/or abortive-
lytic replication of EBV to affect the innate immune response.
There are reports showing that in vitro acute and persistent
infections with EBV result in changes in the secretion patterns
of TNF-a, IL-1, IL-6, and IL10 (Fayad et al., 2001; Gosselin et
al., 1992a, 1992b; Tanner et al., 1996). There are several
studies that show that increases in proinflammatory cytokines
are upregulated in patients with EBV-associated diseases.
Increases in serum levels of TNF-a, IL-1h, IL-6, IL-8, and
IL-10 levels in patients with EBV-associated lymphomas have
been described (Klein et al., 1996; Kurzrock, 2001; Luciani et
al., 1998; Mori et al., 2003; Sharma and Zhang, 2001), and
serum levels of both IL-6 and IL-10 have been correlated with
disease outcome in Hodgkin’s disease patients with higher
levels predictive of a poorer health outcome (Fayad et al.,
2001; Lai et al., 2002). IL-10 which is produced by activated
monocytes and T- and B-cell lymphomas can inhibit the
production of IL-1, IL-2, IL-6, and IFN-g (Mosmann, 1994).
The EBValso encodes for a viral IL-10 (V-IL10), a homologue
to cellular IL-10; VIL-10 can inhibit the production of IFN-g
and IL-1. This cytokine pattern would result in favoring the
survival of EBV since IL-10 can inhibit the induction of EBV-
specific cytotoxic T-cells to latent EBV-infected growth and
malignantly transformed cells (Kanno et al., 1997; Rickinson et
al., 1992). It is of interest that, in a recent study, increased
levels of IL-10 were also observed in serum from NPC patients
and in the NPC tumor cells (Budiani et al., 2002).
We have also shown that the EBV-encoded dUTPase can
induce immune dysregulation in vivo in mice. Confirming the
results from this in vitro study, EBV-encoded dUTPase inhibited
mitogen-stimulated blastogenesis of lymph node and spleenic-
derived lymphocytes recovered frommice inoculated with EBV-
encoded dUTPase. Decrements in the synthesis of IFN-g were
also observed. Importantly, the mice inoculated with the
dUTPase demonstrated sickness behavior known to be induced
by some of the same cytokines that were found to be upregulated
in this study. Compared to control mice, the dUTPase-treated
mice lost body mass, had elevated body temperatures, and
diminished locomotor activity (Padgett et al., 2004).
In summary, there is evidence in the literature to support the
hypothesis that viral proteins, by themselves, can induce
immune dysregulation. For example, the 15e kDa polypeptide
of the feline leukemia virus (FeLV) significantly inhibits
replication of mitogen-stimulated feline lymphocytes in vitro
(Mathes et al., 1979). Furthermore, a recombinant peptide, HIV-
1 env–gag, suppressed the synthesis of IgG by pokeweed
mitogen-treated human B-lymphocytes; the same recombinant
R. Glaser et al. / Virology 346 (2006) 205–218214peptide significantly increased the proliferative response of
PBMCs as compared with control cultures (Nair et al., 1988). As
already discussed, data from two recent studies show that
purified EBV LMP-1 and gp350 can induce immune dysregula-
tion (D’Addario et al., 2000; Dukers et al., 2000). These viral-
encoded proteins are either capsid/envelope components or are
expressed on the membranes of latently infected cells. In con-
trast, the EBV-encoded dUTPase is a non-structural EA protein.
As already discussed, patients with specific clinical histories
have unique antibody patterns to several EBV-encoded
enzymes including the dUTPase. The mechanism(s) underlying
the process that results in such antibody patterns is not known.
The availability of these EBV early proteins to induce an
antibody response would result from the lysis of cells in which
the latent EBV genome was fully reactivated. It is also possible
that early proteins like the dUTPase can be released by cells
undergoing abortive reactivation (Deng et al., 2004; Glaser et
al., 1991, 2005). In such cells, an early protein(s), e.g., viral
encoded enzyme(s), may be synthesized and expressed on the
surface of the cell as an HLA-restricted immunodominant
target for CTLs and be capable of inducing an antibody
response (Steven et al., 1997).
The data presented in this paper and the paper in which the
EBV-encoded dUTPase was shown to induce sickness behavior
in mice (Padgett et al., 2004) provide a new perspective on the
role of an EBV-encoded early non-structural protein in the
pathophysiology of EBV-associated disease. Whether other
early proteins can induce immune dysregulation needs to be
explored. However, the data from this study and others
(D’Addario et al., 2000; Dukers et al., 2000; Mathes et al.,
1979; Nair et al., 1988) show that at least some of the viral-
encoded proteins can produce changes in both humoral and
cellular immunity separate from their roles in virus replication/
latency. The data may have implications for understanding the
role of EBV and other herpesviruses in diseases/syndromes of
unknown etiology, such as chronic fatigue syndrome (Glaser et
al., 2005; Gotleib-Stematsky and Glaser, 1982).
Materials and methods
Purification of EBV-encoded dUTPase
The EBV-encoded dUTPase gene (BLLF3) was cloned into
a pET3A vector, which was kindly provided by Peter Sommer
(Institut fur Mikrobiologic und Hygiene, Abteilung Virolgie).
The plasmid was maintained in E. coli (BL21EBVdUT) using
ampicillin (100 Ag/ml) selection. The EBV-encoded dUTPase
(Mr = 31 kDa) was purified to apparent homogeneity using
Blue Sepharose affinity chromatography. Briefly, BL21EBV-
dUT was grown in LB medium containing chloramphenicol
(25 Ag/ml) and ampicillin (100 Ag/ml) at 37 -C for 2.5 h. IPTG
(1 mM final concentration) was added, and the culture was
incubated an additional 2 h at 37 -C. Bacteria were collected
from 6 l of medium by low speed centrifugation, and the
bacterial pellet was resuspended in 50 ml of extraction buffer
(10 mM Tris–HCL, pH 7.5, 1 mM MgCl2, 2 mM 2-
mercaptoethanol, and a protease inhibitor cocktail containingantipain, benzamidine, chymostatin, leupeptin, pepstatin,
TLCK, and TPCK at a final concentration 1 Ag/ml each).
Bacteria were lysed by ultrasonication. The resulting homog-
enate was centrifuged (15,000g, 30 min at 4 -C), and the
supernatant was applied to a Blue Sepharose (Sigma Chemical
Co.) column (2.5  25 cm) equilibrated with extraction buffer.
The matrix was washed with equilibration buffer and equili-
bration buffer containing 1 M NaCl (500 ml each), and the
EBV-encoded dUTPase was eluted using a linear gradient of 1
M to 2 M NaCl in equilibration buffer.
Under these conditions, the E. coli dUTPase is not retained
on the matrix, while the EBV-encoded dUTPase is retained and
begins to elute at approximately 1.6 M NaCl. Fractions
containing maximal dUTPase activity were combined and
concentrated using Centriprep-30 (Amicon, Beverly, MA).
EBV-encoded dUTPase activity was determined as described
previously using the DE81 filter disc assay (Cheng et al.,
1980). A unit of dUTPase activity was defined as the amount
of enzyme required to convert 1 nmol of dUTP to dUMP and
pyrophosphate per min at 37 -C under the assay conditions.
The specific activity of the EBV-encoded dUTPase prepara-
tions used in these studies ranged from 450 to 750 units/mg of
protein. Protein concentration was determined with the
Coomassie Brilliant Blue dye-binding assay (Bio-Rad Labora-
tories) using bovine serum albumin as the standard. To rule out
endotoxin contamination in our protein preparations, dUTPase
preparations were assayed for endotoxin using the Limulus
Amebocyte Lysate Kit (BioWhittaker), which can detect an
endotoxin concentration of 0.06 IU/ml.
Several additional assays were performed to eliminate the
possibility that our purified EBV-encoded dUTPase prepara-
tions were contaminated with other bacterial components
such as DNA, RNA, and peptidoglycan. High sensitivity
Quant-iTi kits (Molecular Probes) were used to detect possible
DNA and RNA contamination. The Quant-iTi DNA HS assay
can detect double-stranded (ds) DNA down to 1 ng/ml, while
the Quant-iTi RNA assay has a detection limit of 5 ng/ml. For
the detection of peptidoglycan, the silkworm larvae plasma
(SPL) assay (Wako Chemicals) was employed. The SLP assay
not only detects peptidoglycan but also h-glucan, a cell wall
component of fungi. The SLP-HS assay has a detection limit of
10 pg/ml of peptidoglycan. The purified EBV-encoded dUT-
Pase, which was stored at 4 -C at stock concentrations of 0.5
and 1 mg/ml, was used for these studies.
The purity of EBV-encoded dUTPase was determined by
capillary-liquid chromatography–nanospray tandem mass
spectrometry (nano-LC/MS/MS). Briefly, the EBV-encoded
dUTPase was digested essentially as described previously
(Russell et al., 2001). The EBV-encoded dUTPase preparation
was desalted using manual syringe protein traps (Michrom
BioResources; Auburn, CA) and resuspended in 10 Al of water.
Dithiothreitol (5 Al of a 5 mg/ml solution in 100 mM
ammonium bicarbonate) was added to reduce the cysteines.
The solution was heated at 50 -C for 15 min, cooled, and
iodoacetamide (5 Al of a 15 mg/ml solution in 100 mM
ammonium bicarbonate) was added and reacted in the dark at
room temperature for 15 min. Sequencing grade trypsin (20 ng/
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1:25 trypsin to EBV-encoded dUTPase, and the final buffer
conditions for digestion were 25 mM ammonium bicarbonate
and 40% acetonitrile. The digestion was performed at 37 -C for
4 h and stopped by acidification with 1 Al of trifluoroacetic
acid.
Nano-LC/MS/MS was performed on a Micromass, a hybrid
quadrupole time-of-flight Q-TOFi II (Micromass, Wythen-
shawe, UK) mass spectrophotometer equipped with an
orthogonal nanospray source (New Objective, Inc., Woburn,
MA) operated in positive ion mode. The LC system was an
UltiMate Plus System (LC-Packings) with a Famous auto-
sampler and Switchos column switcher. Solvent A was water
containing 50 mM acetic acid, and Solvent B was acetonitrile.
Each sample (2.5 Al) was first injected on the trapping column
and then washed with 50 mM acetic acid. The peptides were
eluted off the trap onto the column, and an ID ProteoPep C18
column (5 cm, 75 AM; New Objectives, Inc.) packed directly in
the nanospray tip was used for chromatographic separations.
Peptides were eluted from the column into the Q-TOFi
system using a gradient of 2–80% Solvent B over 50 min with
a flow rate of 300 nl/min. A total run time was 55 min. The
nanospray capillary voltage was set a 3.0 kV and the cone
voltage at 55 V. The source temperature was maintained at 100
-C. Mass spectra were recorded using MassLynx 4.0 with
automatic switching functions. Mass spectra were acquired
from mass 400 to 2000 Da every second with a resolution of
8000 (FWHM). When the desired peak (using included tables)
was detected at a minimum of 15 ion counts, the mass
spectrophotometer automatically switched to acquire CID MS/
MS spectrum of the individual peptides. Collision energy was
set dependent on charge state recognition properties. Sequence
information from the MS/MS data was processed using Mascot
Distiller (http://www.Matrixscience.com/). Database searches
were performed using Mascot from Matrix Science and
PEAKS from Bioinformatics Solutions.
Sequence information from the MS/MS data was processed
using Mascot Distiller to form a peaklist (.mgf file). Data
processing was performed following established guidelines
(Carr et al., 2004). Briefly, data were minimally processed, a 3-
point smooth was applied, and the centroid was calculated from
the top 80% of the peak height. The charge state of each ion
selected for MS/MS was calculated, however, the peaks were
not deisotoped. Assigned peaks have a minimum of 5 counts
(S/N of 3) and must show the corresponding C13 ion to be
considered valid. The mass accuracy of the precursor ions was
set to 1.2 Da to accommodate accidental selection of the C13
ion, and the fragment mass accuracy was set to 0.3 Da.
Considered modifications (variable) were methionine oxidation
and carbamidomethyl cysteine. NCBInr was the database used
in the search.
The effect of EBV-encoded dUTPase on human T-cell
replication and cytokine production
In order to determine if EBV-encoded dUTPase affected
human T-cell replication and function in vitro, experimentswere performed with PBMCs obtained from the American Red
Cross from healthy donors through an Ohio State University-
approved IRB protocol. We did not determine if the subjects
who provided the blood samples were latently infected with
EBV and, therefore, seropositive for the virus. However, since
we showed in a previous study that approximately 90% of
adults are seropositive for EBV, it is probable that most, if not
all, of our subjects were seropositive (Glaser et al., 1985).
PBMCs were isolated by density gradient centrifugation
using Histopaque-1077 (Sigma) by routine procedures. To
induce T-cell proliferation, PBMCs (0.5  106 cells/ml) were
treated with an anti-CD3 monoclonal antibody (mAb)
(Coulter Clone UCHT1) for 72 h in the presence of either
7.5 Ag/ml or 15 Ag/ml of purified EBV-encoded dUTPase
(total volume 0.1 ml). For negative controls, cells were
treated with buffer or human g-globulin, which was used as a
non-specific protein control as described in previous studies
(D’Addario et al., 2000; Dukers et al., 2000; Nair et al., 1988;
Voo et al., 2002).
Blastogenesis was measured using the CellTiter 96 Aqueous
Non-Radioactive Cell Proliferation Assay (Promega) using
samples in triplicate. The O.D. value obtained from unstimu-
lated PBMCs T protein was subtracted from the O.D. value
from CD3-stimulated PBMCs T protein. For cytokine studies
(total volumes ranged from 0.2 to 1 ml, depending on the
cytokine), cell cultures were set up in polystyrene round-
bottom tubes at the same cellular and EBV-encoded dUTPase
concentrations used in the blastogenesis assay. Supernatants
were harvested for cytokine analysis at 24, 48, and 72 h. The
cell pellets were resuspended in 0.8 ml Trizol (Invitrogen Life
Technologies) for RNA isolation. Real-time RT-PCR was
performed to measure mRNA levels.
In order to confirm that the observed cytokine induction
profile was a direct result of the EBV-encoded dUTPase and
not LPS contamination, polymyxin B sulfate (Sigma) was
added at 10 Ag/ml in the presence or absence of 10 Ag/ml
EBV dUTPase; supernatants were harvested over a 72
h period as indicated above. Additionally, neutralization
studies were performed in which a mAb to the EBV-encoded
dUTPase 7D6 (Nicholls et al., 1998) or a rat IgG1 isotype
was preincubated at room temperature with 10 Ag/ml EBV
dUTPase for 1 h prior to treatment of PBMCs; the super-
natants were harvested and tested for cytokine analysis as
indicated above.
Cytokine analysis
Concentrations of different cytokines in cell culture super-
natants of resting non-stimulated PBMCs exposed to 7.5 Ag/ml
or 15 Ag/ml of the EBV-encoded dUTPase were measured with
commercially available human cytokine ELISA kits or by flow
cytometry. Buffer-treated cells were used as negative controls.
Specifically, IL-2, IL-4, and IL-5 concentrations were measured
using the Human Th-1/Th-2 Cytokine Cytometric Bead Array
Kits (BD Biosciences). IL-1h, IL-6, IL-8, IL-10, IL-12p70, and
TNF-a concentrations were measured with the Human Inflam-
mation Cytometric Bead Array Kits (BD Biosciences). IFN-g
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from Biosource International. The minimal detectable concen-
tration for each cytokine is as follows: 6.6 pg/ml for IL-2; 6.5 pg/
ml for IL-4; 2.8 pg/ml for IL-5; 7.2 pg/ml for IL-1h; 2.5 pg/ml
for IL-6; 3.6 pg/ml for IL-8; 3.3 pg/ml for IL-10; 1.9 pg/ml for
IL-12p70; 3.7 pg/ml for TNF-a; and 4 pg/ml for IFN-g.
Real-time RT-PCR analysis
mRNA levels of IL-6, IL-10, IL-8, IL-1h, TNF-a, and
IFN-g were measured using real-time RT-PCR analysis on
total RNA obtained from PBMCs treated with EBV-encoded
dUTPase for 24 h and from control cultures. Total RNA from
PBMCs was extracted with Trizol reagent (Invitrogen Life
Technologies) according to the manufacturer’s suggested
protocol. The genomic DNA was sheared in the sample by
passing twice through a 26-gauge needle connected to a 1 ml
syringe. Total RNA was precipitated with isopropanol in the
presence of glycogen (Roche Applied Science) at 200 Ag/ml
as a carrier. The total RNA pellet was resuspended in
RNAse-free water (Ambion) and stored at 80 -C until
analysis.
RNA was reverse-transcribed from 500 ng of total RNA
with random hexamers and Superscript II (Invitrogen Life
Technologies). Real-time RT-PCR was performed using the
Rotor-Gene sequence detector (Corbett Research). The cycle
parameters for the PCR were set up according to the
manufacturer’s suggestion. Gene-specific primers and probes
(TaqMan PDARS) for IL-1h, IL-6, IL-8, IL-10, IFN-g, and
GAPDH were purchased from Applied Biosystems; the TNF-a
primer and probe were gifts from Michael Caliguiri. Relative
quantitations of cytokine mRNA expression were calculated
with the comparative Ct method. Each target cytokine value
was divided by the endogenous reference GAPDH value to
obtain a normalized target value.
Depletion analysis
Based on our preliminary results, which suggested the
involvement of macrophages/monocytes (CD14+ cells), we
performed experiments to remove CD14+ cells from PBMCs
using Magnetic Cell Sorting (MACS) Microbeads (Miltenyi
Biotec, Germany). Depletion of CD14+ cells was performed
according to the manufacturer’s instructions. Briefly, 9 ml of
PBMCs at approximately 6  106 cells/ml was plated onto a
150  25 mm polystyrene tissue culture plate for 4 h at 37 -C/
5% CO2. Non-adherent cells were gently washed from the
plate with Ca2+/Mg2+-free PBS, incubated with CD14
Microbeads at the manufacturer’s suggested concentration,
washed, and applied successively to two LS Separation
Columns (Miltenyi Biotec, Germany). Column flow-through
was analyzed by flow cytometry to confirm removal of the
specific cell type using CD14-FITC (Miltenyi Biotec Clone
TU¨K4). An adherent fraction was also collected from the
tissue culture plate after incubating with Ca2+/Mg2+-free PBS
at 4 -C for an hour. CD14-depleted non-adherent cells (0.5 
106 cells/ml) and adherent cells (0.1  106) were treated with10 Ag/ml EBV-encoded dUTPase over 72 h for cytokine
analysis. Additional experiments were conducted in which the
adherent cells were added back to the CD14-depleted popula-
tion at a percentage of total non-adherent cells (i.e., 1  105
adherent cells represented 20% of 5  105 CD14-depleted non-
adherent cells) and treated with 10 Ag/ml EBV-encoded
dUTPase over 72 h for cytokine analysis. The number of
CD14+ cells varied per adherent preparation; the actual number
of CD14+ cells added back was determined from flow analysis
of the adherent fraction.
Statistical analysis
Statistical analyses were performed using a paired two-
sample t test for the means. Results are shown as the mean T
SEM. Two-tailed P values are reported when significant
(P < 0.05). Nonlinear regression analysis was performed using
Tukey’s cubic transformations. The coefficients of correlation
(r) are reported within the figures. Further analysis revealed
that 75–83% of the residuals fell within T1 Se and 100%
within T2 Se.
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